GlassScriptPhysician profile
Charles W Mcgee
NPI 1811498959
$854.87
in general payments reported to CMS, 2019-2025
15 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $118 · 2024: $494 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $281.74 | 2024-2025 | Korlym |
| Smith+Nephew, INC. | $117.01 | 2023-2024 | Collagenase Santyl, Renasys Touch, Regranex |
| Amgen INC. | $79.88 | 2024-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $79.53 | 2024 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $65.95 | 2023-2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.22 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $36.14 | 2025 | Airsupra |
| Lundbeck LLC | $23.65 | 2023 | Rexulti |
| Optinose US, INC. | $21.72 | 2025 | |
| Organogenesis INC. | $20.96 | 2025 | Via Matrix |
| Mimedx Group, INC. | $20.84 | 2025 | |
| Hartmann USA, INC. | $20.54 | 2023 | Zetuvit Plus |
| Lilly USA, LLC | $16.70 | 2023 | Mounjaro |
| Dexcom, INC. | $15.75 | 2023 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $14.24 | 2024 | Dovato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.